Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients With Palmoplantar Pustulosis: Results of A Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study
mediaposted on 2021-04-14, 13:24 authored by Adis journals on behalf of:, Ulrich Mrowietz, A David Burden, Andreas Pinter, Kristian Reich, Knut Schäkel, Patrick Baum, Yakov Datsenko, Hongjie Deng, Steven J Padula, Christian Thoma, Robert Bissonnette
Article full text
The above summary slide and video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.